OC
CRL icon

Oppenheimer & Co’s Charles River Laboratories CRL Stock Holding History

Oppenheimer & Co’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,745
Closed -$473K – 1446
2024
Q1 		$473K Buy
+1,745
New +$417K 0.01% 1011
2023
Q1 		– Sell
-1,486
Closed -$324K – 1394
2022
Q4 		$324K Buy
+1,486
New +$325K 0.01% 1057
2022
Q1 		– Sell
-1,635
Closed -$616K – 1491
2021
Q4 		$616K Buy
1,635
+178
+12% +$69.2K 0.01% 961
2021
Q3 		$601K Sell
1,457
-5
-0.3% -$2.08K 0.01% 942
2021
Q2 		$541K Buy
1,462
+34
+2% +$11.4K 0.01% 999
2021
Q1 		$414K Sell
1,428
-1,159
-45% -$322K 0.01% 1040
2020
Q4 		$646K Sell
2,587
-3
-0.1% -$714 0.01% 791
2020
Q3 		$587K Sell
2,590
-23
-0.9% -$4.77K 0.01% 755
2020
Q2 		$456K Buy
2,613
+545
+26% +$87K 0.01% 833
2020
Q1 		$261K Sell
2,068
-1,062
-34% -$159K 0.01% 944
2019
Q4 		$478K Sell
3,130
-40
-1% -$5.54K 0.01% 851
2019
Q3 		$420K Hold
3,170
– – 0.01% 860
2019
Q2 		$450K Sell
3,170
-84
-3% -$11.4K 0.01% 854
2019
Q1 		$473K Sell
3,254
-47
-1% -$6.17K 0.01% 847
2018
Q4 		$374K Sell
3,301
-249
-7% -$31.2K 0.01% 850
2018
Q3 		$478K Buy
3,550
+863
+32% +$107K 0.01% 883
2018
Q2 		$302K Buy
2,687
+11
+0.4% +$1.19K 0.01% 1061
2018
Q1 		$286K Buy
+2,676
New +$288K 0.01% 1081
2014
Q2 		– Sell
-4,209
Closed -$254K – 1419
2014
Q1 		$254K Buy
+4,209
New +$245K 0.01% 1117

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.4B AUM 49.36% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Oppenheimer & Co's CRL Position: Q2 2024 in Review

Oppenheimer & Co sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 1,745 shares — an estimated $473K sold.

Oppenheimer & Co first reported a position in CRL in Q1 2014 and held it in 19 quarters. The position peaked at $646K in Q4 2020. 665 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

  • Oppenheimer & Co reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
  • Oppenheimer & Co sold 1,745 Charles River Laboratories shares in Q2 2024, an estimated $473K.
  • Oppenheimer & Co first reported a position in Charles River Laboratories in Q1 2014 and held it in 19 quarters.
  • Oppenheimer & Co's Charles River Laboratories position peaked at $646K in Q4 2020.
  • 665 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Oppenheimer & Co's 13F filing for Q2 2024, filed 8 Aug 2024.